Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Kylie Prutisto-Chang"'
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Emily Chin, Cyril H. Benes, Sara Stevens, Subba R. Digumarthy, Ashish Saxena, Alice T. Shaw, Beow Y. Yeap, Rebecca J. Nagy, Christopher G. Azzoli, Hetal D. Marble, Jessica J. Lin, Justin F. Gainor, Adam Langenbucher, Kylie Prutisto-Chang, Andrew Do, Jochen K. Lennerz, Satoshi Yoda, Nathaniel A. Adams, Marguerite Rooney, Aaron N. Hata, Michael S. Lawrence, Audris Oh, Ibiayi Dagogo-Jack
Publikováno v:
Clin Cancer Res
Purpose: Most ALK-positive lung cancers will develop ALK-independent resistance after treatment with next-generation ALK inhibitors. MET amplification has been described in patients progressing on ALK inhibitors, but frequency of this event has not b